Holen Sie sich die Stockscreener-App
3.035
2.41%
-0.075
Schlusskurs vom Vortag:
$3.11
Offen:
$3.1
24-Stunden-Volumen:
483.24K
Relative Volume:
0.42
Marktkapitalisierung:
$427.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.44M
KGV:
-8.6714
EPS:
-0.35
Netto-Cashflow:
$-42.28M
1W Leistung:
-2.10%
1M Leistung:
+105.07%
6M Leistung:
+166.23%
1J Leistung:
+116.79%
1-Tages-Spanne:
$2.87
$3.1352
1-Wochen-Bereich:
$2.525
$3.63
52-Wochen-Spanne:
$0.765
$3.63
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie CMPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.03 | 427.90M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.36 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.55 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.73 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.18 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.57 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Eingeleitet | Jefferies | Buy |
| 2023-01-27 | Eingeleitet | Stifel | Buy |
| 2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
| 2021-12-22 | Eingeleitet | Raymond James | Outperform |
| 2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Compass Therapeutics stock hits 52-week high at $3.14 - MSN
Biliary Tract Cancer Market Poised for Significant Growth from - openPR
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Compass Therapeutics stock hits 52-week high at $3.14 By Investing.com - Investing.com South Africa
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Can Compass Therapeutics' Tovecimig Chart A New Direction In The Treatment Of Biliary Tract Cancers? - RTTNews
Is Compass Therapeutics, Inc. (CMPX) the Hottest Smid-Cap Stock So Far In 2025? - Insider Monkey
Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Growth in Short Interest - Defense World
Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 5.2% - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Barclays PLC - Defense World
Barclays PLC Purchases 112,614 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - MarketBeat
2025 catalysts: Bispecifics poised to enter new era - BioCentury
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Earns “Outperform” Rating from William Blair - Defense World
VerifyMe (NASDAQ: VRME) Enters Agreement with Institutional Investor for $4.7 Million Proceeds - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Alliance Global Partners Initiates Coverage on TMC the metals (NASDAQ:TMC) - Defense World
Compass Therapeutics stock hits 52-week high at $2.68 - MSN
TANG CAPITAL MANAGEMENT LLC Increases Stake in Compass Therapeutics Inc - GuruFocus.com
Compass Therapeutics stock hits 52-week high at $2.68 By Investing.com - Investing.com UK
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Jane Street Group LLC Trims Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Biliary Tract Cancer Market Expected to Experience Major Growth - openPR
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Windtree Therapeutics Announces New Corporate Strategy in Recent Press Release - Defense World
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.com - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
KBW Regional Banking Index (KRX) QuotePress Release - The Globe and Mail
Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate - GlobeNewswire
Another Day, Another Biotech Stealing The Show - MSN
Nasdaq Industrial Index (INDS) QuotePress Release - The Globe and Mail
TSX High Income Energy USD Index (TXHU) QuotePress Release - The Globe and Mail
TSX Health Care Capped Index (TTHC) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Stock Market Movers Today • Top Gainers & Losers - Benzinga
KBW Finsec Dividend Yield Index (KDX) QuotePress Release - The Globe and Mail
CMPX stock touches 52-week high at $2.35 amid market fluctuations - Investing.com Canada
Compass Therapeutics' (CMPX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
D. Boral Capital Reaffirms "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics reports progress on cancer treatments - Investing.com
US Penny Stocks To Watch In January 2025 - Simply Wall St
Geode Capital Management LLC Buys 128,655 Shares of FutureFuel Corp. (NYSE:FF) - Defense World
Golden Entertainment, Inc. (NASDAQ:GDEN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Geode Capital Management LLC Acquires 19,095 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in ON24, Inc. (NYSE:ONTF) - Defense World
Geode Capital Management LLC Raises Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Tucows Inc. (NASDAQ:TCX) Shares Bought by Barclays PLC - Defense World
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.41%
5.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):